Chemin des Aulx 14
About Calypso BiotechCalypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.
CEO: Alain Vicari
CSO: Yolande Chvatchko
Please click here for Calypso Biotech job opportunities.
Please click here for clinical trial information.
5 articles about Calypso Biotech
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization, produces a GMP-grade clinical batch of CALY-002 for Calypso Biotech.
Calypso Biotech BV Secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases
Calypso Biotech, an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing co-led by Gilde Healthcare and Inkef Capital.
AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002
AGC Biologics and Calypso Biotech B.V. announced that they have entered into an agreement for the process development and cGMP manufacture of CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15.